Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
40 hedge funds and large institutions have $88.2M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
5% more funds holding
Funds holding: 38 → 40 (+2)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
2% less capital invested
Capital invested by funds: $89.9M → $88.2M (-$1.72M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$516K |
| 2 |
State Street
Boston,
Massachusetts
|
+$174K |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$158K |
| 4 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$112K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$376K |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$196K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$117K |
| 4 |
BlackRock
New York
|
-$55.4K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$36.4K |
ELOX Hedge Fund Activity: Q1 2019 in Review
40 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q1 2019, worth a combined $88.2M — down 1.9% from $89.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ELOX positions and 1 closed out — a net gain of 2 holders — while 13 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $516K. The largest seller was Morgan Stanley, cutting an estimated $376K.
- 40 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q1 2019, up from 38 in Q4 2018.
- Funds reported $88.2M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q1 2019, down 1.9% quarter-over-quarter.
- 3 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q1 2019 and 1 closed out, a net change of +2 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q1 2019 was Vanguard Group, an estimated $516K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q1 2019 was Morgan Stanley, an estimated $376K sold.
Based on aggregated 13F filings for Q1 2019.